Literature DB >> 6673083

Consumption of refined sugar by patients with Crohn's disease, ulcerative colitis, or irritable bowel syndrome.

G Järnerot, I Järnmark, K Nilsson.   

Abstract

The daily dietary consumption of refined sugar was studied in four equal-sized groups of 30 patients with Crohn's disease, ulcerative colitis (UC), irritable bowel syndrome (IBS), or minor orthopedic conditions. The latter group was matched for sex and age with the Crohn's disease group. The Crohn's disease patients consumed significantly more refined sugar (88.9 +/- 50.7 (SD) g/day) than the controls (64.3 +/- 45.6 g/day), the UC patients (64.3 +/- 38.7), or the IBS patients (59.9 +/- 33.3). Fifteen patients with Crohn's disease interviewed within 6 months of diagnosis consumed similar amounts of sugar (69.9 +/- 43.9) to those of the subjects in the other three groups. Fifteen other patients with Crohn's disease studied 7-36 months after diagnosis consumed significantly more refined sugar (107.9 +/- 41.2). These results indicate that the high sugar consumption in Crohn's disease is a secondary phenomenon without etiologic importance.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6673083     DOI: 10.3109/00365528309181832

Source DB:  PubMed          Journal:  Scand J Gastroenterol        ISSN: 0036-5521            Impact factor:   2.423


  16 in total

1.  Pre-illness changes in dietary habits and diet as a risk factor for inflammatory bowel disease: a case-control study.

Authors:  Giovanni Maconi; Sandro Ardizzone; Claudia Cucino; Cristina Bezzio; Antonio-Giampiero Russo; Gabriele Bianchi Porro
Journal:  World J Gastroenterol       Date:  2010-09-14       Impact factor: 5.742

Review 2.  [What is the role of nutrition in Crohn disease? A contribution to the importance of dietary therapy in regional enteritis].

Authors:  E Nagel; H Canzler; R Pichlmayr
Journal:  Langenbecks Arch Chir       Date:  1991

3.  Environmental risk factors in paediatric inflammatory bowel diseases: a population based case control study.

Authors:  S Baron; D Turck; C Leplat; V Merle; C Gower-Rousseau; R Marti; T Yzet; E Lerebours; J-L Dupas; S Debeugny; J-L Salomez; A Cortot; J-F Colombel
Journal:  Gut       Date:  2005-03       Impact factor: 23.059

4.  A 3D Polymer Model for Future Nutrition Design Novel Nutrition Approach for Cystic Fibrosis, Ulcerative Colitis and Crohn's Disease.

Authors:  Paul Zarogoulidis; Ioannis Kioumis; Theodora Tsiouda; Nikolaos Pezirkianidis; Christos Ritzoulis; Haidong Huang; Wolfgang Hohenforst-Schmidt; Dionysios Spyratos; Konstantinos Porpodis; Georgia Pitsiou; Sofia Lampaki; John Organtzis; Bianca Kathryn Malecki; Sindre Ervik Saetre; Konstantinos Zarogoulidis; Marek Malecki
Journal:  J Nanomedine Biotherapeutic Discov       Date:  2014-08

5.  Pre-illness dietary factors in inflammatory bowel disease.

Authors:  S Reif; I Klein; F Lubin; M Farbstein; A Hallak; T Gilat
Journal:  Gut       Date:  1997-06       Impact factor: 23.059

6.  Controlled multicentre therapeutic trial of an unrefined carbohydrate, fibre rich diet in Crohn's disease.

Authors:  J K Ritchie; J Wadsworth; J E Lennard-Jones; E Rogers
Journal:  Br Med J (Clin Res Ed)       Date:  1987-08-29

7.  Smoking and sugar intake are separate but interactive risk factors in Crohn's disease.

Authors:  B Katschinski; R F Logan; M Edmond; M J Langman
Journal:  Gut       Date:  1988-09       Impact factor: 23.059

Review 8.  The Role of Diet in Inflammatory Bowel Disease.

Authors:  Raina Shivashankar; James D Lewis
Journal:  Curr Gastroenterol Rep       Date:  2017-05

9.  Evidence-based clinical practice guidelines for Crohn's disease, integrated with formal consensus of experts in Japan.

Authors:  Fumiaki Ueno; Toshiyuki Matsui; Takayuki Matsumoto; Katsuyoshi Matsuoka; Mamoru Watanabe; Toshifumi Hibi
Journal:  J Gastroenterol       Date:  2012-10-23       Impact factor: 7.527

10.  Smoking and Crohn's disease.

Authors:  K W Somerville; R F Logan; M Edmond; M J Langman
Journal:  Br Med J (Clin Res Ed)       Date:  1984-10-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.